

# Co-administration of Coenzyme Q10 and HMG-CoA Reductase Inhibitor Attenuates Oxidative Stress, TGF- $\beta$ , TNF- $\alpha$ , Nitrite Content and MPO Levels against Experimentally-induced Diabetic Nephropathy in Rats

Rajesh A. Maheshwari<sup>1\*</sup>, Ashim Kumar Sen<sup>1</sup>, Ramachandran Balaraman<sup>1</sup>, Nirmal V. Shah<sup>1</sup>, Umang H. Shah<sup>2</sup>, Nilay Solanki<sup>2</sup>, Dhanya B. Sen<sup>1</sup>

<sup>1</sup>Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Piparia, Waghodia, Vadodara, INDIA.

<sup>2</sup>Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Anand, Gujarat, INDIA

## ABSTRACT

**Objectives:** Diabetes is a major disease that causes a tremendous economic burden internationally. To tackle this horrible condition, good therapeutic intervention with nutraceutical is required. These include diabetic nephropathy, which ranges from chronic kidney disease to end-stage renal failure. Thus, this study used nutraceutical such coenzyme Q10 and HMG-CoA reductase inhibitor (rosuvastatin) to see how beneficial they are in treating diabetic nephropathy. **Materials and Methods:** The animal experiments were conducted to induce nephropathy by using streptozotocin-nicotinamide. Animals were divided into five groups such as control, diabetic control, coenzyme Q10, rosuvastatin and their combination. The renal function test was conducted by estimating uric acid, creatinine and urea. Antioxidant parameters were assessed by evaluating MDA, SOD, GSH and catalase activity in renal tissue. Levels of MPO, TGF- $\beta$ , TNF- $\alpha$  and nitrite concentration were measured together with alterations in histopathology in the kidneys were observed in every treated animal. **Results:** Diabetic rats were studied for signs of nephropathy, and the results showed elevated levels of urea, creatinine, uric acid, MPO activity, TGF- $\beta$ , TNF- $\alpha$ , nitrite and MDA as well as decreased levels of GSH, SOD and CAT activity. It was shown that when coenzyme Q10 and rosuvastatin were given combined, renal function tests improved far more quickly than when the two medications were given separately. **Conclusion:** This study found that combination therapy improved renal function and controlled free radical production, inflammatory mediators, and histological alterations that lead to kidney injury.

**Keywords:** Diabetic nephropathy, MPO activity, TNF- $\alpha$ , TGF- $\beta$ , Coenzyme Q10.

Submission Date: 28-03-2022;

Revision Date: 14-06-2022;

Accepted Date: 07-08-2022.

DOI: 10.5530/ijper.56.4.190

**Correspondence:**

**Dr. Rajesh A. Maheshwari**

Department of Pharmacy,  
Sumandeep Vidyapeeth  
(Deemed to be University),  
Piparia, Waghodia,  
Vadodara-391760, Gujarat,  
INDIA.

Email: rajpharma2007@gmail.com

## INTRODUCTION

Most deaths and illnesses related to diabetes are caused by complications such as nephropathy and other cardiovascular diseases in those with type 2 diabetes.<sup>1</sup> In most of the cases, end-stage renal failure occurs due to diabetic nephropathy (DN).<sup>2</sup> As diabetic renal disease advances, proteinuria, a symptom of underlying DN, often develops swelling of the basement membrane and sclerosis of the mesangial cells in the kidneys are two of the most

common symptoms of glomerular filtration rate decline. Increased levels of advanced glycation end products (AGEs), which lead to kidney damage in diabetics, have been linked to hyperglycemia.<sup>3,4</sup> It has been found that oxidative stress also play a key role in the development of DN.<sup>5</sup>

Presence of protein in urine and the development of chronic kidney disease (CKD) to end-stage renal disease (ESRD) can be slowed with angiotensin-converting



www.ijper.org

enzyme inhibitors or angiotensin receptor antagonists. Many patients, on the other hand, fail to respond to these medications and develop ESRD at an early stage.<sup>6</sup> Dietary antioxidants may help delay or prevent diabetic complications, according to a prior study.<sup>7,8</sup>

Ubiquinone, another name for coenzyme Q10, is a vitamin-like molecule found in the phospholipid bi-layer of cell membranes, where it is lipid-soluble and hydrophobic. Different types of foods such as fish, red meat, nuts, and edible oils are rich with this nutrient.<sup>9</sup> Anti-inflammatory, antiulcer, antioxidant, and anti-diabetic effects of coenzyme Q10 have previously been demonstrated.<sup>9-12</sup> Additionally, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors have numerous other favourable benefits, including the capacity to decrease cholesterol.<sup>13</sup>

Antioxidants like coenzyme Q10 and/or rosuvastatin were suggested to investigate their renoprotective effects in nephropathy. DN caused by STZ-nicotinamide was the focus of this study, which sought to see if coenzyme Q10 alone or in combination with rosuvastatin could provide protection.

## MATERIALS AND METHODS

### Drugs and Chemicals

Zydus Cadila, Ahmedabad, India, provided rosuvastatin and coenzyme Q10. Himedia (Mumbai, India) supplied the streptozotocin and nicotinamide. The study's kits were purchased from a standard company. Reagents and chemicals of analytical quality were utilized in the proposed work.

### Experimental animals

This present research was permitted by IAEC which is official authority for the maintenance of experimental animals in all institutions. Wistar rats (200-250g) were housed in polypropylene cages and day night cycle of 12hr at 24°C with humidity of 35 to 60%. Water for drinking and diet for nutrition were provided.

### Induction of diabetic nephropathy

The experimentally-initiated DN was conducted as per the earlier protocol.<sup>14,15</sup>

### Experimental design

The experimental animals were divided into five groups which are as follows:

Experimental group 1 (a): Normal control group (distilled water 10 ml/kg, p. o.)

Experimental group 2 (b): Diabetic control group

Experimental group 3(c): Coenzyme Q10 (10 mg/kg in 1% Tween 80 solution in water, p. o.)<sup>16</sup>

Experimental group 4 (d): Rosuvastatin (10 mg/kg, p. o.)<sup>17</sup>

Experimental group 5 (e): Coenzyme Q10 + Rosuvastatin DN was not carried out in experimental group 1 as it was in the other groups. The six-week treatment regimens for all of the aforementioned groups began on the seventh day following STZ-NA injection.

Glycated haemoglobin (HbA<sub>1c</sub>) was calculated using whole blood. We used a standard diagnostic kit to assess the levels in the serum of uric acid, creatinine, and urea. For the purpose of collecting urine for testing, all animals were housed in metabolic cages for a period of 24 hr. In order to determine urinary micro protein levels, centrifugation of urine samples were carried out for five minutes at 1400 rpm and the supernatant was collected.

Renal indicators of oxidative stress include glutathione (GSH), catalase (CAT)/ superoxide dismutase (SOD) and malondialdehyde (MDA) were previously assessed by means of pre-existing methodologies.<sup>18-21</sup> The activity of MPO in renal tissue was assessed in accordance with the study's instructions.<sup>22</sup> The levels of TGF- $\beta$  and TNF- $\alpha$  in kidney tissue homogenates were assessed making use of ELISA kits. Using the Griess reagent, we determined the quantity of nitrite in the protein-free supernatant of kidney homogenate.<sup>23</sup>

### Histopathology

Kidney was extracted and kept in formalin (10 percent phosphate buffer), and processed for histological evaluation after the experimental animals from the aforementioned groups were sacrificed, as previously reported.<sup>17</sup>


### Statistical analysis

For the assessment of degree of significance ( $p < 0.05$ ) for all tests (one-way ANOVA), Bonferroni multiple comparison test was utilized. The data were displayed as Mean  $\pm$  SEM.

## RESULTS

### Effect of Coenzyme Q10 and Rosuvastatin on Urinary Protein and Volume

In comparison with untreated control rats, diabetic untreated rats had higher urine volumes and urine proteins, as seen in Figures 1A-B, indicating kidney impairment. Neutraceutical or anti-hyperlipidemic treatment or their combination demonstrated a positive response in the reduction of urine volume and protein. However, coenzyme Q10 and rosuvastatin were administered together, urine protein levels were



**Figure 1: Effect of coenzyme Q10 and rosuvastatin on (A) urinary protein and (B) urine volume.**

Values are expressed as mean ± SEM; n=6.  
 a vs. b, <sup>###</sup>p < 0.001;  
 b vs. c, b vs. d and b vs. e, <sup>\*</sup>p < 0.05, <sup>\*\*</sup>p < 0.01, <sup>\*\*\*</sup>p < 0.001;  
 c vs. e, <sup>###</sup>p < 0.001; d vs. e, <sup>###</sup>p < 0.001

significantly altered than monotherapy (coenzyme Q10 or rosuvastatin).


**Effect of coenzyme Q10 and rosuvastatin on uric acid, urea, creatinine and HbA1c levels**

Diabetic control rats had considerably greater levels of glycated haemoglobin compared to normal untreated animals. Rosuvastatin and/or coenzyme Q10 were found to lower glycated haemoglobin levels in diabetic animals than diabetic untreated rats. Glycated haemoglobin levels were not affected by coenzyme Q10 + rosuvastatin treatment in comparison with monotherapy.

Diabetic untreated rats had noticeable elevation in urea, uric acid, creatinine levels significantly as compared to those in normal untreated rats, indicating a serious decline in renal function. A single intraperitoneal injection of STZ-nicotinamide appears to impede kidney function, according to these data. Therapy with coenzyme Q10 and/or rosuvastatin resulted in considerable reductions in urea, uric acid, creatinine concentrations in diabetic rats. Coenzyme Q10 + rosuvastatin medication reduced serum creatinine and urea levels more than monotherapy did (Figure 2 A-D).

**Effect of coenzyme Q10 and rosuvastatin on HDL-C, Triglyceride and Total cholesterol levels**

The levels of total cholesterol, triglycerides, and HDL-C in diabetic rats were significantly different from those in non-diabetic rats. In comparison with diabetic untreated rats, administration of coenzyme Q10 and/or



**Figure 2: Effect of coenzyme Q10 and rosuvastatin on (A) glycated hemoglobin (B) serum creatinine (C) serum urea and (D) serum uric acid.**

Values are expressed as mean ± SEM; n=6.  
 a vs. b, <sup>###</sup>p < 0.001;  
 b vs. c, b vs. d and b vs. e, <sup>\*</sup>p < 0.05, <sup>\*\*</sup>p < 0.01, <sup>\*\*\*</sup>p < 0.001;  
 c vs. e, <sup>\*</sup>p < 0.05, <sup>###</sup>p < 0.001; d vs. e, <sup>\*</sup>p < 0.05.


rosuvastatin lowered total cholesterol, triglycerides, and increased HDL-C level. Coenzyme Q10 in conjunction with rosuvastatin, on the other hand, had a greater impact on triglyceride and HDL-C levels than coenzyme Q10 alone (Figure 3 A-C).

**Effect of coenzyme Q10 and rosuvastatin on TNF-α, myeloperoxidase activity, TGF-β and nitrite level**

It was found that diabetic control rats had considerably greater renal levels of TNF-α, MPO activity, TGF-β, and nitrite content compared to study’s normal animals. Aforementioned biomarkers were significantly reduced in renal tissue when treated with coenzyme Q10 and/or rosuvastatin than diabetic untreated animals. Coenzyme Q10 plus rosuvastatin reduced TNF-α and nitrite levels more than coenzyme Q10 or rosuvastatin alone in diabetic rats. Additionally, combination therapy was more effective than monotherapy of coenzyme Q10 at reducing MPO activity (Figure 4 A-D).


**Effect of coenzyme Q10 and rosuvastatin on markers of oxidative stress in renal tissue**

We discovered after six weeks that MDA, an oxidative stress marker, was higher in diabetes control rat’s renal tissue than non-diabetic rats. Antioxidant like GSH, CAT and SOD were decreased in kidney tissue. Diabetic rats administered coenzyme Q10 and/or rosuvastatin had lower MDA and higher SOD, CAT, and GSH levels than diabetic control rats. MDA, SOD and GSH levels were considerably affected more when both used together than monotherapy of rosuvastatin (Figure 5 A-D).




**Figure 3: Effect of coenzyme Q10 and rosuvastatin on (A) Total Cholesterol (B) Triglyceride (C) HDL-C.**

Values are expressed as mean ± SEM; n=6.  
 a vs. b, ### p < 0.001;  
 b vs. c, b vs. d and b vs. e, \*p < 0.05, \*\*\*p < 0.001;  
 c vs. e, ^p < 0.05, ^^p < 0.001.



**Figure 4: Effect of coenzyme Q10 and rosuvastatin on (A) TNF-α (B) TGF-β (C) MPO and (D) NO.**

Values are expressed as mean ± SEM; n=6.  
 a vs. b, ### p < 0.001;  
 b vs. c, b vs. d and b vs. e, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001;  
 c vs. e, ^p < 0.05; d vs. e, ^p < 0.05.



**Figure 5: Effect of coenzyme Q10 and rosuvastatin on (A) MDA (B) SOD (C) CAT and (D) GSH.**


Values are expressed as mean ± SEM; n=6.  
 a vs. b, ### p < 0.001;  
 b vs. c, b vs. d and b vs. e, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001;  
 d vs. e, ^p < 0.05, ^p < 0.01.

**Histopathological Studies**

Glomeruli and tubules in the normal control group were found to be normal in histological examination of kidney tissue. The thickening of the glomerular basement membrane (#), tubular vacuolization (\*), interstitial fibrosis (+), and glomerulosclerosis (\$) in diabetic rats were observed in the renal tissue sections. Moderate glomerular necrosis, interstitial fibrosis, tubular vacuolization, and glomerular basement membrane thickening were noted with coenzyme Q10 or rosuvastatin. No glomerulosclerosis was seen with coenzyme Q10 and rosuvastatin treatment, but mild tubular oedema, interstitial fibrosis, and thickening of the glomerular basement membrane (Figure 6).

**DISCUSSION**

It is among the main reasons of illness and death of mankind because of chronic renal disease.<sup>24</sup> In biomedical research, treating DN is a challenge. In our previous study, it was shown that experimentally induced DN characterised by elevated blood creatinine, BUN, uric acid, urine protein, TGF-β, TNF-α, MPO release and nitrite.<sup>25,26</sup> From the above study it was thought interesting to extend the our work by administering coenzyme Q10 and rosuvastatin in DN model. There is evidence that antioxidants like resveratrol and coenzyme Q10 can aid in the treatment of kidney disease, particularly in the case of DN.<sup>27,28</sup> Diabetic rats given coenzyme Q10 and rosuvastatin had considerably lower levels of elevated haemoglobin A1C, urea, creatinine, uric acid, and urinary protein than diabetic rats who were not given these treatment. These findings support the prior study that showed statins can help to prevent



**Figure 6: Light microscopy of kidney tissues from rats (HE stained kidney sections).**

(A) Normal control group, (B) Diabetic control group, (C) Coenzyme Q10 (D) Rosuvastatin (E) Coenzyme Q10 + Rosuvastatin.

microalbuminuria and nephropathy.<sup>29,30</sup> Furthermore, in the study, the combination resulted in a significant alteration in lipid biomarkers. Despite being an anti-lipidemic medicine, rosuvastatin has been shown to prevent experimentally induced DN when given alone or in combination with an antioxidant such coenzyme Q10.

Reactive oxygen species (ROS) like hydroxyl radicals, superoxide anion, hydrogen peroxide, and lipid peroxidation products such as malondialdehyde have been associated to DN aetiology.<sup>1,31,32</sup> The current study found a rise in oxidative stress due to STZ-nicotinamide injection. GSH, CAT and SOD contents were considerably greater in rats with treatment of coenzyme Q10 and/or rosuvastatin. However, combined therapy had a stronger effect on oxidative stress indicators.

The progression of DN is mostly due to metabolic and hemodynamic variables. This effect is caused by TGF- $\beta$ , TNF- $\alpha$ , and MPO release.<sup>33,34</sup> Diabetes rats treated with coenzyme Q10, rosuvastatin, or both had lower levels of kidney TGF- $\beta$ , TNF- $\alpha$  and MPO than diabetes rats not treated. Concurrent dosing of coenzyme Q10 and rosuvastatin exhibited a greater renoprotective effect,

reducing the above indicators. It has previously been shown that high nitrite levels are caused by peroxynitrite produced by NO interacting with superoxide radicals.<sup>35</sup> Our investigation found that coenzyme Q10 and rosuvastatin reduced kidney nitrite levels in diabetic rats.

## CONCLUSION

These findings show that coenzyme Q10 or rosuvastatin have renoprotective effects against DN. The combination of coenzyme Q10 and rosuvastatin provided a greater renoprotective effect than monotherapy. This may be due to decreased lipid peroxidation, TGF- $\beta$ , TNF- $\alpha$ , MPO, and nitrite levels in kidney tissue. Finally, combined therapy may help prevent DN.

## ACKNOWLEDGEMENT

We are sincerely thankful to Sumandeep Vidyapeeth (Deemed to be University) for providing financial support to carry out the study.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

## ABBREVIATIONS


**DN:** Diabetic Nephropathy; **AGEs:** Advanced Glycation End Products; **CKD:** Chronic Kidney Disease; **ESRD:** End Stage Renal Disease; **ROS:** Reactive Oxygen Species; **STZ:** Streptozotocin; **NA:** Nicotinamide; **TGF- $\beta$ :** Transforming Growth Factor - beta; **TNF- $\alpha$ :** Tumor Necrosis Factor - alpha; **MPO:** Myeloperoxidase; **BUN:** Blood Urea Nitrogen; **IAEC:** Institutional Animal Ethics Committee; **ELISA:** Enzyme Linked Immunosorbent Assay; **MDA:** Malondialdehyde; **SOD:** Superoxide Dismutase; **CAT:** Catalase; **GSH:** Glutathione; **SEM:** Standard Error of the Mean; **HMG-CoA:** 3-hydroxy-3- methylglutaryl-coenzyme A.

## REFERENCES

1. Yan HD, Li XZ, Xie JM, Li M. Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells. *Chin Med J (Engl)*. 2007;120(9):787-93. doi: 10.1097/00029330-200705010-00010, PMID 17531120.
2. Barnett A. Prevention of loss of renal function over time in patient with diabetic nephropathy. *Am J Med*. 2006;119(5);Suppl 1:S40-7. doi: 10.1016/j.amjmed.2006.01.013, PMID 16563947.
3. Lee SH, Heo SJ, Hwang JY, Han JS, Jeon YJ. Protective effects of enzymatic digest from *Ecklonia cava* against high glucose-induced oxidative stress in human umbilical vein endothelial cells. *J Sci Food Agric*. 2010;90(2):349-56. doi: 10.1002/jsfa.3833, PMID 20355053.

4. Aljofan M, Ding H. High glucose increases expression of cyclooxygenase-2, increases oxidative stress and decreases the generation of nitric oxide in mouse micro vessel endothelial cells. *J Cell Physiol.* 2010;222(3):669-75. doi: 10.1002/jcp.21986, PMID 19950211.
5. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old diagram. *Diabetes.* 1999;48(1):1-9. doi: 10.2337/diabetes.48.1.1, PMID 9892215.
6. Bos H, Andersen S, Rossing P, Zeeuw DD, Parving HH, Jong PE. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. *Kidney Int.* 2000;57(Suppl 75):S32-7. doi: 10.1046/j.1523-1755.2000.07506.x
7. Makni M, Sefi M, Fetoui H, Garoui El M, Gargouri NK, Boudawara T, *et al.* Flax and pumpkin seeds mixture ameliorates diabetic nephropathy in rats. *Food Chem Toxicol.* 2010;48(8-9):2407-12. doi: 10.1016/j.fct.2010.05.079, PMID 20570704.
8. Punithavathi VR, Prince PSM, Kumar R, Selvakumari J. Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic Wistar rats. *Eur J Pharmacol.* 2011;650(1):465-71. doi: 10.1016/j.ejphar.2010.08.059, PMID 20863784.
9. Kamei M, Fujita T, Kanbe T, Sasaki K, Oshiba K, Otani S, *et al.* The distribution and content of ubiquinone in foods. *Int J Vitam Nutr Res.* 1986;56(1):57-63. PMID 3710719.
10. Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F. Functions of coenzyme Q10 in inflammation and gene expression. *BioFactors.* 2008;32(1-4):179-83. doi: 10.1002/biof.5520320121, PMID 19096114.
11. Kohli Y, Suto Y, Kodama T. Effect of hypoxia on acetic acid ulcer of the stomach in rats with or without coenzyme Q10. *Jpn J Exp Med.* 1981;51(2):105-8. PMID 7277789.
12. Lenaz G, Fato R, Formigini G, Genova ML. The role of coenzyme Q10 in mitochondrial electron transport. *Mitochondrion.* 2007;7Suppl:S8-33. doi: 10.1016/j.mito.2007.03.009, PMID 17485246.
13. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: Lipid reduction and beyond. *J Clin Endocrinol Metab.* 2002;87(4):1451-8. doi: 10.1210/jcem.87.4.8412, PMID 11932263.
14. Kamble HV, Bodhankar SL. Trigonelline and sitagliptin attenuates nicotinamide-streptozotocin induced diabetic nephropathy in Wistar rats. *Int J Pharm Pharm Sci.* 2013;5(4):583-9.
15. Maheshwari RA, Khatri S, Sailor GU, Balaraman R. Antidiabetic activity of Dibolin (a polyherbal formulation) in streptozotocin-nicotinamide induced type 2 diabetic rats. *Int J Pharm Pharm Sci.* 2014;2:893-7.
16. Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y, Garjani A, *et al.* Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. *Eur J Pharmacol.* 2011;666(1-3):135-41. doi: 10.1016/j.ejphar.2011.04.061, PMID 21570962.
17. Maheshwari RA, Sailor GU, Patel L, Balaraman R. Amelioration of cisplatin-induced nephrotoxicity by statins. *Indian J Pharmacol.* 2013;45(4):354-8. doi: 10.4103/0253-7613.115016, PMID 24014910.
18. Slater TF, Sawyer BC. The stimulatory effect of carbon tetrachloride and other halogenalkane or peroxidative reaction in the rat liver functions *in vitro*. *Biochem J.* 1971;123(5):805-14. doi: 10.1042/bj1230805, PMID 4399399.
19. Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay of superoxide dismutase. *J Biol Chem.* 1972;247(10):3170-5. doi: 10.1016/S0021-9258(19)45228-9, PMID 4623845.
20. Aebi H. Catalase *in vivo*. *Meth Enzymol.* 1984;105:121-6. doi: 10.1016/S0076-6879(84)05016-3.
21. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. *Biochim Biophys Acta.* 1979;582(1):67-78. doi: 10.1016/0304-4165(79)90289-7, PMID 760819.
22. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. *Gastroenterology.* 1984;87(6):1344-50. doi: 10.1016/0016-5085(84)90202-6, PMID 6092199.
23. Guevara I, Iwanejko J, Dembińska-Kieć A, Pankiewicz J, Wanat A, Anna P, *et al.* Determination of nitrite/nitrate in human biological material by the simple Griess reaction. *Clin Chim Acta.* 1998;274(2):177-88. doi: 10.1016/S0009-8981(98)00060-6, PMID 9694586.
24. Ntemka A, Iliadis F, Papanikolaou N, Grekas D. Network-centric analysis of genetic predisposition in diabetic nephropathy. *Hippokratia.* 2011;15(3):232-7. PMID 22435020.
25. Maheshwari R, Balaraman R, Sen AK, Shukla D, Seth A. Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats. *Ren Fail.* 2017;39(1):130-9. doi: 10.1080/0886022X.2016.1254659, PMID 27841100.
26. Maheshwari RA, Balaraman R, Sen AK, Seth AK. Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats. *Indian J Pharmacol.* 2014;46(6):627-32. doi: 10.4103/0253-7613.144924, PMID 25538335.
27. Mohamed NAR. Effect of resveratrol, curcumin and metformin on streptozotocin induced diabetic nephropathy in rats. *J Am Sci.* 2012;8(8):731-8.
28. Ahmadvand H. Effects of coenzyme Q10 on hemoglobin A1C, serum urea and creatinine in alloxan-induced type 1 diabetic rats. *Iran J Pharmacol Ther.* 2012;11(2):64-7.
29. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, *et al.* HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. *Nephrol Dial Transplant.* 2003;18(2):265-72. doi: 10.1093/ndt/18.2.265, PMID 12543879.
30. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. *Diabetologia.* 2003;46(6):843-51. doi: 10.1007/s00125-003-1099-3, PMID 12774163.
31. Booth AA, Khalifah RG, Todd P, Hudson BG. *In vitro* kinetic studies of formation of antigenic advanced glycation end products (AGEs): Novel inhibition of Post-amadori glycation pathways. *J Biol Chem.* 1997;272(9):5430-7. doi: 10.1074/jbc.272.9.5430, PMID 9038143.
32. Miyoshi H, Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, *et al.* Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. *Horm Metab Res.* 2002;34(7):371-7. doi: 10.1055/s-2002-33478, PMID 12189584.
33. David S, Peter M. Understanding diabetic nephropathy-is there a genetic susceptibility. *Eur Endocrinol.* 2008;4:66-9.
34. Kettle AJ, Van Dalen CJ, Winterbourn CC. Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. *Redox Rep.* 1997;3(5-6):257-8. doi: 10.1080/13510002.1997.11747120, PMID 9754322.

## PICTORIAL ABSTRACT



## SUMMARY

Diabetes is a global economic burden. Diabetes can cause chronic kidney disease and end-stage renal failure. Nutraceuticals are needed to treat this dreadful disease. The present study was employed to treat DN with coenzyme Q10 and rosuvastatin. Animals were given streptozotocin-nicotinamide to induce nephropathy. Five groups of animals: control, diabetes control, coenzyme Q10, rosuvastatin, and their combination. Serum Uric acid, creatinine, urea, MDA, SOD, GSH and catalase activities in renal tissue were evaluated. MPO activity, TGF- $\beta$ , TNF- $\alpha$ , and nitrite levels, as well as kidney histology were assessed, in every treated animal. Diabetic rats revealed higher levels of urea, creatinine, uric acid, MPO activity, TGF- $\beta$ , TNF- $\alpha$ , nitrite, and MDA and decreased GSH, SOD, and CAT activity. Coenzyme Q10 and rosuvastatin combination improved kidney function test by virtue of altering the abovementioned parameters.

## About Authors



**Dr. Rajesh A. Maheshwari** is Professor at Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, India. He has also been honored with Member of National Academy of Medical Sciences, India (MAMS) in 2017 for his contribution towards the Medical Research. In addition to this, he has also been conferred for the "Sumandeep Vidyapeeth Research Award" for two times i.e. in 2015-16 and 2018-19. He has published more than 50 research papers in International and National Journals of repute.



**Dr. Ashim Kumar Sen** currently working as Professor at Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara-391760, Gujarat, India. He has published 80 research papers in International and National Journals of repute. In addition to this, he has also been conferred for the "Sumandeep Vidyapeeth Research & Innovation Award" for 2019-20. He guided 3 students for PhD and more than 25 students for M. Pharm.



**Dr. R. Balaraman**, FAMS is one of the senior and eminent pharmacologists having over 44 years of experience in teaching and research. He guided 20 students for PhD and more than 50 for M. Pharm. He has published more than 130 research papers in International and National journals of repute. His research papers have over 2500 citations with 'h'-index 27. Dr. Balaraman has many academic achievements to his credit. In 2002 he was elected as the Member of National Academy of Medical Science (MAMS). He was subsequently elected as a Fellow of The Academy of Medical Science (FAMS) for the year 2009 due to his academic excellence and his contribution to the advancement of medical science.



**Dr. Nirmal Shah** is working as a Professor at Department of Pharmacy, Sumandeep Vidyapeeth, Deemed to be University, Vadodara. He has more than 15 years of Academic, Research, and Pharmaceutical Industry experience. So far, he has published more than 80 scientific papers in reputed national and international journals. He is editor of 1 book published in Springer Nature Singapore Pte Ltd.



**Dr. Nilay Solanki** is working as Associate Professor at Ramanbhai Patel College of Pharmacy, CHARUSAT Campus, Changa, Gujarat, India. He has total 15 years of research and academic experience in the Pharmacology field. He has received government funded projects (ICMR, SSIP) worth above 10 lacs. He has received CHARUSAT research paper awards for consecutive four years from 2017 to 2020 and have published over 30 research papers in peer review journals.



**Dr. Umang Shah** is working as an Assistant Professor at Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Gujarat. Dr. Shah working on Analytical methods development and validation, Pharmacological Screening of Compounds, Drug discovery and design area. Dr. Shah has published more than 52 research/review articles and 02 book chapters and 02 books. Dr. Shah is one of the popular authors of "Complete Companion for GPAT and other Competitive Examinations in Pharmacy" from Pearson Publication. Dr. Shah has received more than 10 awards in various National and International Conferences. Dr. Shah received "Best Talent Award from Association of Pharmacy Profession (APP) and "Best Research Paper Award" from Charotar University of Science and Technology.



**Dr. Dhanya B. Sen** currently working as Associate Professor at Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara-391760, Gujarat, India. She has published 50 research papers in International and National Journals of repute. She guided 3 students for PhD and more than 15 students for M. Pharm.

**Cite this article:** Maheshwari RA, Sen AK, Balaraman R, Shah NV, Shah UH, Solanki N, Sen DB. Co-administration of Coenzyme Q10 and HMG-CoA Reductase Inhibitor Attenuates Oxidative Stress, TGF- $\beta$ , TNF- $\alpha$ , Nitrite Content and MPO Levels against Experimentally-induced Diabetic Nephropathy in Rats. *Indian J of Pharmaceutical Education and Research*. 2022;56(4):1091-8.